Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD 0360324 and cyclophosphamide in recurrent platinum-resistant ovarian cancer
NCT02948101Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-0360324 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse effect at 90 days, Density of CD8+ T cells in tumor biopsies at 90 days and 3 more. Planned start Dec 2018; status: withdrawn.
02
Drugs
PD-0360324
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02948101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948101.